omicron: Big News: The first indigenous vaccine coming on omicron, a big company in Pune

New Delhi : India will soon get the first messenger or mRNA vaccine on corona. Genova Biopharmaceuticals will complete the third phase of the vaccine trial. The other good news is that the same company has developed a covid vaccine on omicron specifically. Messenger platform is also used for this.

The company will produce in Pune

Genova Biopharmaceuticals of Pune, Maharashtra has recently handed over the second phase of test data to the Drug Regulator. The second-dose mRNA vaccine, developed on a delta variant of the SARS-CoV2 virus, has been tested on 3,000 people in the second phase. The company will now also complete the third phase of testing, sources said.

Awaiting regulator approval from the company

The company has started risk manufacturing of vaccines. Adequate vaccine production will be done after getting approval from the regulator. The new vaccine is also unlikely to get regulatory approval. Vaccines prepared in such cases are at risk of being wasted. Hence the risk of vaccine manufacturing.

On the other hand, a vaccine targeting Omicron has been developed in the laboratory of Genova Pharmaceuticals. And now the vaccine will be tested on humans to find out its effects and immunity, the sources said.

covid vaccine: Center says no one can be forced to get vaccinated against their will

The first vaccine developed from the mRNA platform

The head of the National Task Force on Corona, Dr. VK Paul provided information in this regard. The development of the corona vaccine on the mRNA platform is a major scientific achievement for the country. The special thing is that the existing cold chain infrastructure in the country will be compatible with the new vaccine stock. “Once the vaccine is developed on the mRNA platform, not only Kovid but also other vaccines will be developed on this platform without any hassle,” he said. Paul said.

Omicron Updates: Omicron will affect everyone, but …; The biggest claim about Corona

The specific vaccine on omicron being manufactured by the company is also very special. This is because the vaccine can be modified in the future if a new strain of the virus emerges. The Central Drugs Standards Control Organization (CDSCO) will study the test data submitted by the company and decide whether to approve the vaccine. President of the National Technical Advisory Group on Corona Vaccine, Dr. N. K. This information was given by Arora.